INTERVENTION 1:	Intervention	0
Nab-paclitaxel/Gemcitabine	Intervention	1
Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle	Intervention	2
nanoparticle	CHEBI:50803	5-17
day	UO:0000033	73-76
day	UO:0000033	93-96
day	UO:0000033	150-153
day	UO:0000033	170-173
gemcitabine	CHEBI:175901	107-118
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically or cytologically confirmed invasive breast cancer	Eligibility	1
breast cancer	DOID:1612	51-64
- Clinical evidence of metastatic disease	Eligibility	2
disease	DOID:4,OGMS:0000031	34-41
+ No bone metastases or other non-measurable disease as the only evidence of metastasis	Eligibility	3
disease	DOID:4,OGMS:0000031	45-52
Measurable disease, defined as at least 1 measurable lesion	Eligibility	4
disease	DOID:4,OGMS:0000031	11-18
- The following are considered non-measurable disease:	Eligibility	5
disease	DOID:4,OGMS:0000031	46-53
Small lesions (< 2 cm)	Eligibility	6
Bone lesions	Eligibility	7
Leptomeningeal disease	Eligibility	8
disease	DOID:4,OGMS:0000031	15-22
Ascites	Eligibility	9
ascites	HP:0001541	0-7
Pleural or pericardial effusions	Eligibility	10
Inflammatory breast disease	Eligibility	11
breast disease	DOID:3463	13-27
Lymphangitis cutis or pulmonis	Eligibility	12
lymphangitis	DOID:9317	0-12
Abdominal masses that are not confirmed and followed by imaging techniques	Eligibility	13
Cystic lesions	Eligibility	14
HER2(human epidermal growth factor receptor 2)-positive disease allowed provided patient has received prior treatment with trastuzumab	Eligibility	15
growth factor	BAO:0002024	21-34
receptor	BAO:0000281	35-43
disease	DOID:4,OGMS:0000031	56-63
patient	HADO:0000008,OAE:0001817	81-88
No evidence of active brain metastasis, including leptomeningeal involvement	Eligibility	16
active	PATO:0002354	15-21
brain	UBERON:0000955	22-27
Hormone receptor status:	Eligibility	17
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Not specified	Eligibility	18
PATIENT CHARACTERISTICS:	Eligibility	19
patient	HADO:0000008,OAE:0001817	0-7
Age	Eligibility	20
age	PATO:0000011	0-3
18 and over Sex	Eligibility	21
Female Menopausal status	Eligibility	22
female	PATO:0000383	0-6
Not specified Performance status	Eligibility	23
ECOG 0-1 Life expectancy	Eligibility	24
At least 12 weeks Hematopoietic	Eligibility	25
Absolute neutrophil count  1,500/mm^3	Eligibility	26
Platelet count  100,000/mm^3	Eligibility	27
platelet count	CMO:0000029	0-14
Hemoglobin  9 g/dL Hepatic	Eligibility	28
hemoglobin	CHEBI:35143	0-10
AST and ALT  2.5 times upper limit of normal (ULN)	Eligibility	29
Bilirubin  1.5 times ULN Renal	Eligibility	30
Creatinine  1.5 mg/dL Other	Eligibility	31
creatinine	CHEBI:16737	0-10
Not pregnant or nursing	Eligibility	32
Negative pregnancy test	Eligibility	33
Fertile patients must use effective contraception during and for 30 days after completion of study treatment	Eligibility	34
No pre-existing peripheral neuropathy > grade 1	Eligibility	35
peripheral neuropathy	HP:0009830,DOID:870	16-37
No other clinically significant illness or significant medical condition that would preclude study participation	Eligibility	36
condition	PDRO:0000129	63-72
No history of allergy or hypersensitivity to paclitaxel protein-bound particles in an injectable suspension, paclitaxel, gemcitabine, albumin, drug product excipients, or agents that are chemically similar to study drugs	Eligibility	37
history	BFO:0000182	3-10
allergy	HP:0012393	14-21
hypersensitivity	GO:0002524,DOID:1205	25-41
paclitaxel	CHEBI:45863	45-55
paclitaxel	CHEBI:45863	109-119
suspension	BAO:0002104	97-107
gemcitabine	CHEBI:175901	121-132
drug	CHEBI:23888	143-147
drug	CHEBI:23888	215-219
product	BAO:0003067	148-155
No serious medical risk factors involving any of the major organ systems that would preclude study participation	Eligibility	38
organ	UBERON:0000062	59-64
No active stage III or IV invasive non-breast malignancy within the past 5 years	Eligibility	39
active	PATO:0002354	3-9
PRIOR CONCURRENT THERAPY:	Eligibility	40
Biologic therapy	Eligibility	41
See Disease Characteristics Chemotherapy	Eligibility	42
disease	DOID:4,OGMS:0000031	4-11
No more than 1 prior adjuvant chemotherapy regimen	Eligibility	43
adjuvant	CHEBI:60809	21-29
No prior chemotherapy for metastatic disease	Eligibility	44
disease	DOID:4,OGMS:0000031	37-44
At least 6 months since prior adjuvant or neoadjuvant taxane	Eligibility	45
adjuvant	CHEBI:60809	30-38
adjuvant	CHEBI:60809	45-53
taxane	CHEBI:36064	54-60
More than 2 weeks since prior cytotoxic chemotherapy	Eligibility	46
Prior neoadjuvant chemotherapy allowed	Eligibility	47
No other concurrent chemotherapy Endocrine therapy	Eligibility	48
Prior hormonal treatment as adjuvant therapy or for metastatic disease allowed Radiotherapy	Eligibility	49
adjuvant	CHEBI:60809	28-36
disease	DOID:4,OGMS:0000031	63-70
radiotherapy	OAE:0000235	79-91
Prior radiotherapy to target lesion allowed provided there is evidence of disease progression after completion of treatment	Eligibility	50
radiotherapy	OAE:0000235	6-18
target	BAO:0003064	22-28
disease	DOID:4,OGMS:0000031	74-81
More than 2 weeks since prior radiotherapy, except radiotherapy to a non-target lesion only or single-dose palliative radiotherapy	Eligibility	51
radiotherapy	OAE:0000235	30-42
radiotherapy	OAE:0000235	51-63
radiotherapy	OAE:0000235	118-130
No concurrent radiotherapy Surgery	Eligibility	52
radiotherapy	OAE:0000235	14-26
surgery	OAE:0000067	27-34
Not specified Other	Eligibility	53
More than 2 weeks since prior investigational drugs	Eligibility	54
No concurrent participation in another clinical trial that is studying investigational procedures or therapies	Eligibility	55
Concurrent bisphosphonates (e.g., pamidronate or zoledronate) allowed for palliation of pain or lytic lesions from breast cancer	Eligibility	56
pamidronate	CHEBI:7903	34-45
pain	HP:0012531	88-92
breast cancer	DOID:1612	115-128
Outcome Measurement:	Results	0
Proportion of Patients With Confirmed Responses	Results	1
Confirmed tumor response (complete and partial) as measured by RECIST(Response Evaluation Criteria In Solid Tumors) criteria on 2 consecutive evaluations at least 6 weeks apart.	Results	2
Confirmed tumor response is at least a 30% decrease in the sum of the longest diameter of target lesions and no new lesions.	Results	3
diameter	PATO:0001334	78-86
target	BAO:0003064	90-96
Time frame: Two consecutive evaluations at least 6 weeks apart	Results	4
time	PATO:0000165	0-4
Results 1:	Results	5
Arm/Group Title: Nab-paclitaxel/Gemcitabine	Results	6
Arm/Group Description: Nab (nanoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on 21 day cycle	Results	7
nanoparticle	CHEBI:50803	28-40
day	UO:0000033	96-99
day	UO:0000033	116-119
day	UO:0000033	173-176
day	UO:0000033	193-196
gemcitabine	CHEBI:175901	130-141
Overall Number of Participants Analyzed: 50	Results	8
Measure Type: Number	Results	9
Unit of Measure: participants  Confirmed response: 25	Results	10
Assessable: 50	Results	11
Adverse Events 1:	Adverse Events	0
Total: 11/50 (22.00%)	Adverse Events	1
Anemia 3/50 (6.00%)	Adverse Events	2
anemia	HP:0001903,DOID:2355	0-6
Febrile neutropenia 1/50 (2.00%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Arrythmia 1/50 (2.00%)	Adverse Events	4
Ileus 1/50 (2.00%)	Adverse Events	5
ileus	HP:0002595,DOID:8440	0-5
Nausea 1/50 (2.00%)	Adverse Events	6
nausea	HP:0002018	0-6
Pain-Abdominal 1/50 (2.00%)	Adverse Events	7
Vomiting 1/50 (2.00%)	Adverse Events	8
vomiting	HP:0002013	0-8
Bronchial infection 1/50 (2.00%)	Adverse Events	9
Sepsis 1/50 (2.00%)	Adverse Events	10
sepsis	HP:0100806	0-6
Neutropenia 2/50 (4.00%)	Adverse Events	11
neutropenia	HP:0001875,DOID:1227	0-11
Platelet count decreased 1/50 (2.00%)	Adverse Events	12
platelet count	CMO:0000029	0-14
Dehydration 1/50 (2.00%)	Adverse Events	13
dehydration	HP:0001944	0-11
Arthralgia 1/50 (2.00%)	Adverse Events	14
arthralgia	HP:0002829	0-10
